Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 32.10M | 31.99M | 31.34M | 30.34M | 28.88M | 31.15M |
Gross Profit | 24.33M | 24.04M | 22.90M | 21.54M | 19.90M | 21.49M |
EBITDA | 3.99M | 1.42M | -10.42M | 6.65M | 5.32M | 7.22M |
Net Income | 128.71K | 402.10K | -9.52M | 2.77M | 2.08M | 3.62M |
Balance Sheet | ||||||
Total Assets | 64.38M | 64.68M | 61.22M | 64.89M | 60.66M | 46.20M |
Cash, Cash Equivalents and Short-Term Investments | 3.48M | 3.50M | 980.25K | 1.72M | 8.34M | 10.45M |
Total Debt | 13.86M | 12.93M | 10.90M | 11.61M | 2.82M | 6.24M |
Total Liabilities | 79.04M | 77.89M | 72.25M | 66.41M | 56.48M | 48.87M |
Stockholders Equity | -14.66M | -13.22M | -11.03M | -1.52M | 4.18M | -2.67M |
Cash Flow | ||||||
Free Cash Flow | 4.11M | 3.61M | 1.28M | -8.60M | 974.92K | 8.02M |
Operating Cash Flow | 7.32M | 6.01M | 8.92M | 8.57M | 7.93M | 8.47M |
Investing Cash Flow | -4.82M | -4.88M | -8.14M | -15.28M | -6.95M | 357.49K |
Financing Cash Flow | -2.52M | -979.12K | -2.07M | 147.86K | -3.07M | -5.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $393.86M | 5.04 | -58.97% | ― | 23.81% | 146.45% | |
60 Neutral | HK$15.71B | 5.67 | -7.43% | 4.09% | 11.60% | -21.06% | |
51 Neutral | $53.65M | ― | -59.49% | ― | 21.15% | 46.44% | |
50 Neutral | $40.81M | 404.00 | 93.38% | 11.88% | 2.33% | ― | |
$94.58M | ― | -66.48% | ― | ― | ― | ||
46 Neutral | $50.61M | ― | -290.21% | ― | -100.00% | 44.28% | |
42 Neutral | $39.92M | ― | -71.90% | ― | 69.65% | 27.98% |
Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on Duke’s claim that Cryo-Cell breached the agreement, following Cryo-Cell’s arbitration demand alleging fraudulent inducement and multiple breaches by Duke.
The most recent analyst rating on (CCEL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.
On May 7, 2025, Cryo-Cell International‘s Board of Directors declared a reduced quarterly cash dividend of $0.15 per share, reflecting the current economic environment and capital allocation alternatives. This decision, announced on May 8, 2025, may impact shareholder returns and indicates a cautious approach to financial management amid uncertain economic conditions.